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Summary
Introduction:	Vulnerability	to	psychiatric	manifestations	is	achieved	by	the	influence	
of	genetic	and	environment	including	stress	and	cannabis	consumption.	Here,	we	used	
a	psychosocial	stress	model	based	on	resident-	intruder	confrontations	to	study	the	
brain	corticostriatal-	function,	since	deregulation	of	corticostriatal	circuitries	has	been	
reported	in	many	psychiatric	disorders.	CB1	receptors	are	widely	expressed	in	the	cen-
tral	nervous	system	and	particularly,	in	both	cortex	and	striatum	brain	structures.
Aims and methods:	The	investigation	presented	here	is	addressed	to	assess	the	impact	
of	repeated	stress	following	acute	cannabinoid	exposure	on	behavior	and	corticostri-
atal	brain	physiology	by	assessing	mice	behavior,	the	concentration	of	endocannabi-
noid	and	endocannabinoid-	like	molecules	and	changes	in	the	transcriptome.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial-NoDerivs	License,	which	permits	use	and	distribution	in	any	
medium,	provided	the	original	work	is	properly	cited,	the	use	is	non-commercial	and	no	modifications	or	adaptations	are	made.
©	2018	The	Authors.	CNS Neuroscience & Therapeutics	Published	by	John	Wiley	&	Sons	Ltd.
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1  | INTRODUCTION
Vulnerability	 to	 psychiatric	 disorders	 is	 determined	 by	 the	 inter-
action	of	genetic	and	environmental	 factors1	 such	as	psychosocial	
stress	and	cannabis	consumption.	The	dysregulation	of	corticostri-
atal	 circuitries	 is	 involved	 in	 the	 pathophysiology	 of	 psychotic	
disorders.2	Psychosocial	stress	has	a	remarkable	 influence	on	cen-
tral	 nervous	 system	 (CNS)	 and	 animal	 behavior.3	When	 an	 organ-
ism	 is	 exposed	 to	 a	 stressor,	 biological	 mechanisms	 such	 as	 the	
hypothalamic-	pituitary-	adrenal	axis	(HPA)	and	cardiovascular	read-
justments	come	into	play	to	restore	homeostasis.4	Under	standard	
conditions,	HPA	axis	function	is	mainly	influenced	by	stress,	which	
enhances	 its	 activity,	 and	 the	 circadian	 rhythm.5	 However,	 when	
stress	 is	 prolonged	 over	 the	 time	 and	 the	 activation	 exceeds	 the	
capacity	to	keep	body’s	homeostasis,	psychopathological	sequelae	
can	appear.	Among	the	broad	spectrum	of	brain	structures	closely	
involved	in	anxiety	and	stress	disorders	(for	review	see	Ref.	[6]),	we	
directed	our	efforts	toward	the	dorsal	striatum	(dorsal	CPu)	and	the	
prefrontal	 cortex	 (PFC)	 due	 to	 the	 fact	 that	 these	 areas	 are	 criti-
cally	 involved	 in	social	 relationships.7,8	There	 is	a	growing	body	of	
the	 literature	 that	 suggests	 that	 glucocorticoid	 receptor(s)	 involve	
G	 protein-	dependent	 mechanisms.9	 In	 particular,	 corticostriatal	
activity	 is	modulated	 by	 a	 variety	 of	 G	 protein-	coupled	 receptors	
such	 as	 the	 cannabinoid	 CB1	 receptor,	 which	 is	 highly	 abundant	
in	 the	 CNS.10	 CB1	 receptors	 are	 the	 main	 target	 for	 endogenous	
endocannabinoids	 lipid	 signaling	 molecules	 and	 mediate	 both	
Δ9-	tetrahydrocannabinol	 (THC)	 and	 synthetic	 cannabinoid	 drugs	
pharmacological	 actions.11	 The	main	 endocannabinoids	molecules	
for	 CB1	 receptors	 are	 N-	arachidonylethanolamine	 (AEA)
12 and 
2-	arachidonoylglycerol	 (2-	AG).13 N-	arachidonoylphospatidyletha
nolamine-	specific	 phospholipase	D	 (NAPE-	PLD)	 is	 responsible	 for	
the	production	of	AEA,	while	2-	AG	is	mostly	synthesized	by	diacyl-
glycerol	lipase	(DAGL-	α)	in	the	CNS.14	After	activating	cannabinoid	
receptors,	the	endocannabinoid	AEA	and	related	endocannabinoid-	
like	NAEs	PEA	and	OEA	are	enzymatically	hydrolyzed	by	the	fatty	
acid	amide	hydrolase	(FAAH)	while	2-	AG	is	primarily	metabolized	by	
monoacylglycerol	lipase	(MAGL).15
Interestingly,	the	endocannabinoid	system	has	been	described	to	
have	a	direct	effect	on	both	neurotransmission16	and	glucocorticoid	
signaling.17	Despite	the	lack	of	knowledge	concerning	the	concrete	
corticostriatal	mechanisms	 underlying	 anxiety,	 both	 pharmacologic	
(synthetic	cannabinoid	drugs)	and	behavioral	testing	have	been	ap-
plied.	Thus,	the	aim	of	this	study	was	to	investigate	the	interplay	be-
tween	repeated	long-	term	exposure	to	psychosocial	stress	and	acute	
challenge	with	cannabinoid	drugs	on	mice	corticostriatal	circuitries.	
For	this	purpose,	we	evaluated	the	animals	by	behavioral	testing	and	
then	 quantified	 endocannabinoid	 and	 endocannabinoid-	like	 mole-
cules	and	also	changes	in	whole-	genome	gene	expression	profile.
Results:	Stressed	animals	urinated	frequently;	showed	exacerbated	scratching	activity,	
lower	striatal	N-	arachidonylethanolamine	(AEA)	levels	and	higher	cortical	expression	
of	cholinergic	receptor	nicotinic	alpha	6.	The	cannabinoid	agonist	WIN55212.2	dimin-
ished	locomotor	activity	while	the	inverse	agonist	increased	the	distance	travelled	in	
the	 center	 of	 the	 open	 field.	 Upon	 CB1	 activation,	 N-	oleoylethanolamide	 and	 N-	
palmitoylethanolamide,	two	AEA	congeners	that	do	not	interact	directly	with	cannabi-
noid	 receptors,	 were	 enhanced	 in	 the	 striatum.	 The	 co-administration	 with	 both	
cannabinoids	induced	an	up-regulation	of	striatal	FK506	binding	protein	5.	The	inverse	
agonist	 in	 controls	 reversed	 the	 effects	 of	 WIN55212.2	 on	 motor	 activity.	 When	
Rimonabant	was	 injected	 under	 stress,	 the	 cortical	 levels	 of	 2-	arachidonoylglycerol	
were	maximum.	The	agonist	and	the	antagonist	influenced	the	cortical	expression	of	
cholinergic	receptor	nicotinic	alpha	6	and	serotonin	transporter	neurotransmitter	type	
4	in	opposite	directions,	while	their	co-administration	tended	to	produce	a	null	effect	
under	stress.
Conclusions:	The	endocannabinoid	system	had	a	direct	effect	on	serotoninergic	neu-
rotransmission	and	glucocorticoid	signaling.	Cholinergic	receptor	nicotinic	alpha-	6	was	
shown	 to	be	deregulated	 in	 response	 to	 stress	and	 following	synthetic	cannabinoid	
drugs	thus	could	confer	vulnerability	to	cannabis	addiction	and	psychosis.	Targeting	
the	 receptors	 of	 endocannabinoids	 and	 endocannabinoid-	like	mediators	might	 be	 a	
valuable	option	for	treating	stress-	related	neuropsychiatric	symptoms.
K E Y W O R D S
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2  | MATERIALS AND METHODS
All	animal	experimental	procedures	were	approved	by	University	of	
Göttingen	Institutional	Animal	Care	and	Use	Committee	and	also	were	
in	accordance	with	NIH	guidelines	for	the	use	of	animals	in	research	
and	the	European	Communities	Council	Directive	(86/609/EEC).
2.1 | Animals
A	total	of	120	C57Bl6/J	male	mice	aged	7-	8	weeks	were	purchased	
from	Charles	River	Laboratories	(Sulzfeld,	Germany).	On	arrival,	they	
were	 kept	 five	 per	 cage	 and	maintained	 under	 standard	 conditions	
(12-	hour	light/dark	cycle	with	6:00/18:00	lights	on/off,	a	room	tem-
perature	of	21	±	2°C,	and	food	and	water	ad	libitum).	After	one-	week	
habituation	period,	mice	were	subjected	to	the	experiment.	One-	year-	
old	FVB/N	male	mice	(Charles	River	Laboratories,	Sulzfeld,	Germany)	
were	kept	 individually	and	used	as	 residents.	FVB/N	mice	were	se-
lected	as	residents	because	they	are	more	offensive	than	the	C57Bl/6	
strain.3	The	FVB/N	strain	was	kept	under	the	same	protocol	condi-
tions	as	the	C57Bl/6J	colony	but	housed	in	a	separate	room	to	pre-
vent	the	C57Bl/6J	mice	habituation	to	the	odor	of	the	residents.
2.2 | Drugs
The	CB1/CB2	 receptor	 agonist	WIN55212.2	 (Sigma-	Aldrich,	 Seelze,	
Germany)	 and	 the	 selective	 cannabinoid	 CB1	 receptor	 antagonist	
Rimonabant	(Sequoia	Research	Products	Ltd,	Pangbourne,	UK)	were	
dissolved	 in	 a	 vehicle	 solution	 consisting	 of	 10%	 DMSO	 (Sigma-	
Aldrich,	Seelze,	Germany)	and	0.1%	Tween	80	(Sigma-	Aldrich,	Seelze,	
Germany)	in	0.9%	saline	and	prepared	on	the	21	days	of	the	experi-
ment.	A	volume	of	200	μL	of	drug	and/or	vehicle	was	administered	
intraperitoneally	(WIN55212.2	and	Rimonabant	were	administered	at	
a	concentration	of	3	mg/kg)	before	the	behavioral	testing.
2.3 | Experiment design and experimental groups
The	C57Bl6/J	male	mice	were	sorted	into	two	groups:	Those	exposed	
daily	 to	 psychosocial	 stress	 for	 1	hour	 (stress)	 and	 those	 who	 were	
left	undisturbed	(control).	The	stress	protocol	was	performed	daily	for	
3	weeks.	On	day	21,	the	animals	received	an	appropriate	drug	or	vehicle	
injection	and	then	evaluated	by	behavioral	testing.	Indeed,	control	and	
stressed	mice	were	split	into	four	subgroups	each	(15	animals	per	sub-
group):	mice	treated	twice	with	vehicle	(Veh),	mice	subjected	first	to	ve-
hicle	and	then	WIN55212.2	(WIN),	mice	treated	first	with	Rimonabant	
and	 then	with	WIN55212.2	 (Rim+WIN),	 and	mice	 injected	 first	with	
Rimonabant	and	then	vehicle	(Rim).	Following	the	last	injection	with	ei-
ther	vehicle	or	cannabinoid	drug,	the	animals	were	tested	by	different	
behavioral	paradigms	during	the	rodent	active	phase	(ie,	after	8	pm).
2.4 | Social stress procedure
An	 intruder	 (C57Bl/6J	 mouse)	 was	 placed	 in	 the	 home	 cage	 of	 a	
resident	(FVB/N	mouse),	and	then	they	freely	interacted	until	the	first	
aggression	was	achieved.	After	the	first	attack,	the	C57Bl/6J	mouse	
was	isolated	by	the	use	of	a	small	plastic	wire-	mesh	cage	within	the	
FVB/N	mouse’s	cage	protecting	the	intruder	against	direct	aggression;	
however,	olfactory,	visual,	and	some	vibrissae	contact	with	residents	
were	maintained.	After	1	hour,	the	C57Bl/6J	mouse	was	placed	again	
in	its	home	cage.	To	prevent	habituation,	every	day	intruder	mice	had	
encounters	with	different	residents.	The	psychosocial	stress	protocol	
was	performed	once	per	day	at	a	similar	time	(after	8	pm)	to	enhance	
the	 stress	 prediction	 factor	 in	 intruders.	 In	 contrast,	 controls	 were	
left	 undisturbed	 in	 an	 empty	 cage	 every	day	 for	 1	hour.	 Therefore,	
controls	were	subjected	to	the	same	experimental	protocol	in	terms	
of	handling	and	exposure	to	a	new	environment	(different	cage),	but	
they	did	not	interact	with	the	residents.
2.5 | Behavioral assessment
Mice	 were	 exposed	 to	 psychosocial	 stress	 or	 left	 undisturbed	
for	 21	days.	 On	 day	 21,	 they	 were	 acutely	 treated	 with	 different	
cannabinoid	 drugs	 or	 vehicle	 and	 finally	 evaluated	 by	 behavioral	
testing.	 The	 stress	 paradigm,	 the	 administration	 of	 drugs,	 and	 the	
behavioral	 assessment	 took	 place	 during	 the	 dark	 phase	 (active	
phase).	We	directed	the	behavioral	analyses	by	measuring	locomotor	
and	anxiety-	like	behavior	in	the	open-	field	(OF)	test	and	testing	also	
CNS	 activity	 and	 excitability	 by	 use	of	 the	 functional	 observational	
battery	(FOB).
2.5.1 | Functional observational battery
The	FOB	has	 been	widely	 used	 and	 adapted	 for	 general	 behavioral	
studies	in	mice.18	In	this	study,	the	FOB	test	comprised	28	parameters	
by	which	 the	 investigator	evaluated	CNS	activity	and	excitability	by	
recording	 neuromuscular	 and	 autonomic	 effects,	 and	 sensorimotor	
reactivity.	 There	 were	 four	 consecutive	 testing	 situations:	 (i)	 in	 the	
home	cage,	(ii)	in	the	observer’s	hand,	(iii)	in	the	OF,	and	(iv)	manipula-
tion	tests.	After	a	brief	assessment	in	its	home	cage,	each	mouse	was	
removed	and	handled	by	 the	observer	 to	 evaluate	 ease-	of-	removal,	
handling	 reactivity,	 and	 general	 appearance.	 Then,	 each	mouse	was	
assessed	in	an	OF	arena	(60	cm	×	90	cm)	while	the	observer	analyzed	
CNS	activity,	autonomic	effects,	muscle	tone,	equilibrium,	and	senso-
rimotor	reactivity.	Gait	condition	was	scored	from	1	to	8.	The	gait	was	
scored	as	follows:	normal	gait,	ataxia,	splayed	hind	limbs,	feet	markedly	
splayed	 outward	 from	 the	 body,	 fore-	limb	drag,	walking	 on	 tiptoes,	
hunched	body,	and	body	drag.	The	severity	of	gait	abnormality	was	
also	evaluated	on	a	scale	from	1	(normal)	to	4	(severely	abnormal).18
2.5.2 | Open- field activity
In	the	OF	test,	we	evaluated	the	spontaneous	locomotor	and	explora-
tory	activity	of	mice.	The	experiment	was	conducted	 in	a	Plexiglass	
arena	(45	×	45	×	55	cm),	and	each	mouse	was	left	in	the	same	start-
ing	position.	Animals	were	allowed	to	examine	the	OF	for	10	minutes	
without	habituation.	We	registered	the	total	distance	travelled,	per-
cent	of	time	moving,	time	spent	in	the	center	(defined	as	70%	of	area),	
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hyperactivity	(forward	movement	with	speed	greater	than	20	cm/s),	
and	the	number	of	rearings	by	use	of	the	ActiMot	software	(TSE,	Bad	
Homburg,	Germany)	as	described.3	The	apparatus	was	cleaned	with	
70%	ethanol	p.a.	between	each	test.
2.6 | Brain sample collection and tissue evaluation
Animals	were	sacrificed	immediately	after	OF	task	finished,	and	brain	
tissue	was	collected	accordingly.	All	mice	were	deeply	anesthetized	
by	 intraperitoneal	 injection	of	2,2,2-	tribromoethanol	 (Sigma-	Aldrich,	
Hamburg,	Germany)	and	then	transcardially	perfused	with	cold	0.1%	
phosphate	 buffer	 saline	 (PBS).	 Finally,	 the	 PFC	 and	 the	 dorsal	 CPu	
were	 freshly	 isolated	and	 frozen	 in	 liquid	nitrogen	 for	 LC-	MS,	RNA	
seq,	and	quantitative	RT-	PCR.
2.6.1 | Extraction and measurement of AEA, 2- AG, 
OEA, and PEA levels
The	 endogenous	 lipid	 signaling	 molecules	 AEA	 and	 2-	AG,	 and	
endocannabinoid-	related	 molecules	N-	palmitoylethanolamide	 (PEA),	
and N-	oleoylethanolamide	(OEA)	were	purified	from	the	PFC	and	the	
dorsal	CPu	and	then	quantified	as	described	elsewhere.19	First,	sam-
ples	were	dounce-	homogenized	following	with	chloroform/methanol/
Tris-	HCl	50	mmol/L	pH	7.5	(2:1:1,	v/v)	containing	internal	deuterated	
controls	solution	for	AEA,	2-	AG,	PEA,	and	OEA	measurement	by	iso-
tope	dilution	([2H]8AEA,	[2H]52AG,	[2H]4	PEA,	[2H]4	OEA	(Cayman	
Chemicals,	MI,	USA).	The	lipid	organic	phase	was	dried	down,	weighed,	
and	prepurified	on	silica	gel.	Fractions	were	collected	by	eluting	the	
column	with	99:1,	90:10,	and	50:50	(v/v)	chloroform/methanol.	The	
90:10	fraction	contained	AEA,	2-	AG,	PEA,	and	OEA,	and	it	was	used	
for	 isotopic	 dilution	 liquid	 chromatography-	atmospheric	 pressure	
chemical	 ionization-	mass	spectrometry	quantification	(LC-	APCI-	MS),	
as	previously	described	and	using	 selected	 ion	monitoring	 at	M	+	1	
values	for	the	four	compounds	and	their	deuterated	homologues,	as	
described	in	Ref.	[20]	N	=	4	mice/group.
2.6.2 | RNA extraction
Total	RNA	was	extracted	from	80	samples	 (control	and	stress;	Veh,	
WIN,	 Rim+WIN,	 and	 Rim;	 PFC	 and	 dorsal	 CPu;	 N	=	5	 mice/group)	
using	the	TRIzol	reagent	according	to	the	manufacturer’s	instructions	
(Invitrogen,	NY,	USA).	The	RNA	was	digested	with	RNase-	free	DNase	
(Qiagen,	Düsseldorf,	Germany)	and	checked	 for	 integrity	using	cap-
illary	 gel	 electrophoresis	 (Bioanalyzer,	 Agilent	 Technologies,	 Santa	
Clara,	USA).
2.6.3 | cDNA Library Preparation and RNA Seq
The	library	was	prepared	using	the	TruSeq	RNA	Sample	Preparation	
Kit	(Illumina,	San	Diego,	USA)	starting	from	500	ng	of	total	RNA.	The	
cDNA	libraries	were	quantified	using	the	QuantiFluor	dsDNA	System	
(Promega,	Madison,	USA).	The	size	range	of	the	final	cDNA	libraries	
was	determined	by	the	Bioanalyzer	2100	(Agilent,	Santa	Clara,	USA).	
The	 cDNA	 libraries	 were	 amplified	 and	 sequenced	 using	 cBot	 and	
HiSeq2000	(Illumina,	San	Diego,	USA).
The	sequence	images	were	converted	with	the	Illumina	BaseCaller	
software	 to	bcl	 files,	which	were	demultiplexed	to	FASTQ	files	with	
CASAVA	 version	 1.8.2.	 Quality	 was	 checked	 via	 FastQC	 (version	
0.10.0,	Babraham	Bioinformatics).
2.6.4 | Gene expression analyses
Sequences	were	aligned	to	the	RefSeq21	mouse	transcriptome	using	
bwa,22	 and	 raw	 “hits”	per	 transcript	were	merged	genewise.	DESeq	
was	 used	 to	 analyze	 the	 counts	 per	 gene.23	 The	 resulting	P-	values	
were	corrected	using	Benjamini-	Hochberg	adjustment.24
2.6.5 | Quantitative RT- PCR
The	most	relevant	top	hits	deregulated	by	stress	and	cannabinoid	drugs	
were	further	evaluated	by	quantitative	RT-	PCR.	First-	strand	cDNA	was	
synthesized	 from	1	μg	of	 total	RNA	using	 the	High	Capacity	RNA-	to-	
cDNA	Kit	(Applied	Biosystems,	Darmstadt,	Germany).	mRNA	expression	
was	quantified	by	RT-	PCR	using	the	CXF96TM	Real-	time	PCR	system	
(Bio-	Rad,	Hercules,	USA).	We	used	GAPDH	mRNA	as	an	endogenous	
control.	 TaqMan	 assays	 for	mouse	Chrna6,	Slc6a4, and Fkbp5	 cDNAs	
were	 selected	 from	 validated	 and	 predesigned	 Assays-	on-	Demand	
(Applied	Biosystems,	Darmstadt,	Germany)	 and	used	 in	 real-	time	PCR	
amplifications	 to	detect	 the	expressions	of	Chrna6,	Slc6a4, and Fkbp5. 
The	 reactions	 were	 performed	 in	 triplicate	 using	 2	μL	 of	 cDNA	 in	 a	
10 μL	 reaction	 volume.	 mRNA	 expression	 was	 determined	 using	 the	
comparative	cycle	threshold	(Ct)	method	with	2−ΔΔCt,	according	to	the	
manufacturer’s	instructions	(Applied	Biosystems,	Darmstadt,	Germany).	
cDNAs	were	measured	relative	to	a	“calibrator”	control	sample.	The	2−
ΔΔCt	for	this	“calibrator”	was	arbitrarily	set	to	1.
2.7 | Statistical analysis
A	two-	way	ANOVA	was	used	to	examine	the	effects	of	stress	and	
pharmacological	treatment	on	our	cohort	of	animals.	The	mean	dif-
ferences	 among	 the	 levels	of	one	 factor	were	determined	by	one-	
way	 ANOVA	 or	 Brown-	Forsythe	 test	 when	 applicable.	 Bonferroni	
or	 nonparametric	 Tamhane	 post	 hoc	 test	was	 applied	 for	 pairwise	
comparisons.	Analysis	of	simple	main	effects	was	performed	whether	
there	was	a	significant	interaction	of	the	two	main	factors.	Individual	
comparisons	were	made	using	 the	Student’s	 t	 test.	ANOVA	for	 re-
peated	measures	was	 used	 to	 test	 the	 equality	 of	means	 for	mice	
body	weight.	Significance	level	was	set	to	P	<	0.05.	Data	are	repre-
sented	as	mean	±	SEM.	Significant	 effects	were	 identified	by	SPSS	
(IBM	Corp,	Chicago,	USA).
3  | RESULTS
Results	are	summarized	in	three	main	categories:	(i)	effects	of	stress,	
(ii)	effects	of	drugs,	and	(iii)	effects	of	stress	under	drug	influence.
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3.1 | Effects of stress
We	revealed	a	significant	effect	of	psychosocial	stress	on	body	weight	
throughout	 the	 experimental	 period	 (F(1,	 123)	=	4.84,	 P	<	0.05).	
Indeed,	 exposure	 to	2-	week	 social	 defeat	 paradigm	 significantly	 di-
minished	 body	 weight	 (t(122)	=	2.78,	 P	<	0.01),	 which	 returned	 to	
control	 levels	 by	 the	 end	 of	 the	 stress	 period	 (Figure	1,	 panel	 A).	
Social	defeat	animals	displayed	a	pronounced	scratching	activity	(F(1,	
123)	=	4.06,	 P	<	0.05)	 (Figure	1,	 panel	 B),	 urinated	more	 frequently	
(F(1,	 123)	=	4.97,	 P	<	0.05)	 (Figure	1,	 panel	 C),	 and	 showed	 lower	
levels	of	AEA	(F(1,	18)	=	36.81,	P	<	0.01,	in	the	dorsal	CPu)	(Figure	1,	
panel	D).	Transcriptome	analysis	of	the	selected	brain	structures	re-
vealed	62	top	hits	as	deregulated	genes	by	chronic	psychosocial	stress	
before	 Benjamini-	Hochberg	 adjustment	 (Figure	S1).	 The	 cholinergic	
receptor	nicotinic	alpha	6	(Chrna6),	as	a	candidate	gene,	was	further	
analyzed	 by	 quantitative	 RT-	PCR.	 Thus,	 we	 determined	 that	 long-	
term	exposure	to	stress	increased	the	expression	of	Chrna6	gene	(F(1,	
43)	=	38.32,	P	<	0.01,	in	the	PFC)	(Figure	1,	panel	E)	when	compared	
to	the	nonstressed	group.
3.2 | Effects of drugs
Two-	way	ANOVA	showed	a	significant	main	effect	of	the	drug	treat-
ment	 on	 total	 distance	 traveled	 (F(3,	 121)	=	8.36,	 P	<	0.001),	 dis-
tance	 traveled	 in	 center	 (F(3,	121	=	3.72,	P	<	0.05),	 rearing	 activity	
(F(3,	 121)	=	3.07,	P	<	0.05),	 PEA	 levels	 (F(3,	 17)	=	7.72,	P	<	0.01,	 in	
the	dorsal	CPu),	and	OEA	levels	(F(3,	22)	=	5.29,	P	<	0.01,	in	the	dor-
sal	CPu).	Drug	 administration	had	a	 remarkable	effect	on	 the	 rela-
tive	 fold	 change	 expression	 for	Fkbp5	 (F(3,	 44)	=	11.44,	P	<	0.001,	
in	the	dorsal	CPu).	The	main	effects	of	drug	treatment	were	further	
evaluated	by	one-	way	ANOVA	or	Brown-	Forsythe	test	when	appli-
cable	followed	by	multiple	comparisons	post	hoc	tests	(Table	S1).	In	
the	OF,	 the	cannabinoid	agonist	WIN	decreased	 the	 total	distance	
traveled	(P	<	0.01)	(Figure	2,	panel	A)	while	the	administration	of	the	
inverse	agonist	Rim	significantly	antagonized	such	effects	(P	<	0.01)	
(Figure	2,	 panel	 A).	 Coadministration	 with	 both	 cannabinoid	 drugs	
clearly	reduced	the	total	distance	traveled	in	comparison	with	those	
animals	only	treated	with	Rim	(P	<	0.05)	(Figure	2,	panel	A).	The	dis-
tance	traveled	in	center,	a	measure	of	anxiety-	like	behavior,	was	sta-
tistically	elevated	in	animals	treated	with	Rim	alone	relative	to	mice	
only	treated	with	the	agonist	 (P	<	0.01)	 (Figure	2,	panel	B).	Animals	
were	 also	 observed	 in	 their	 homecage	 by	 registering	 the	 vertical	
movements	 (rearings).	 We	 found	 that	 animals	 treated	 simultane-
ously	with	both	drugs	showed	more	frequent	rearing	behavior	than	
WIN-	treated	animals	(P	<	0.05)	(Figure	2,	panel	C).	The	quantification	
of	the	endocannabinoid-	like	molecules,	PEA	and	OEA,	revealed	the	
highest	amounts	for	these	lipids	in	mice	subjected	to	acute	adminis-
tration	with	the	agonist	(P	<	0.05,	in	the	dorsal	CPu)	(Figure	2,	panel	
D	&	E).	Genomewide	transcriptional	profiling	revealed	two	top	hits	
as	deregulated	genes	by	WIN	and	32	top	hits	as	deregulated	genes	
F IGURE  1 Effects	of	repeated	
exposure	to	psychosocial	stress.	Data	are	
expressed	as	mean	±	SEM.	Exposure	to	
2-	wk	social	defeat	paradigm	significantly	
diminished	body	weight	(P	<	0.01),	which	
returned	to	control	levels	by	the	end	of	
the	stress	period	(panel	A).	Social	defeat	
animals	displayed	a	pronounced	scratching	
activity	(P	<	0.05)	(panel	B),	urinated	more	
frequently	(P	<	0.05)	(panel	C),	and	showed	
lower	levels	of	AEA	content	(P	<	0.01,	in	
the	dorsal	CPu)	(panel	D).	We	determined	
that	long-	term	exposure	to	stress	increased	
the	expression	of	Chrna6	gene	(P	<	0.01,	
in	the	PFC)	(panel	E)	when	compared	
to	controls.	An	*	indicates	significant	
differences	between	stress	group	and	
their	respective	control	group.	One	or	
two	symbols	indicate	P < 0.05; P	<	0.01,	
respectively.	N	=	15	for	behavioral	testing,	
n	=	4	for	endocannabinoids	quantification;	
n	=	5	for	whole-	genome	gene	expression.	
PFC,	prefrontal	cortex;	dorsal	CPu,	dorsal	
striatum;	CTR,	control;	STS,	stress;	AEA,	
N-	arachidonylethanolamine
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by	 Rim	 before	 Benjamini-	Hochberg	 adjustment	 (Figure	S1).	 The	
candidate	gene	 (Fkbp5)	was	validated	by	quantitative	RT-	PCR,	 and	
main	results	are	depicted	in	Figure	2	(panel	F).	We	measured	higher	
transcription	rate	for	Fkbp5	after	administration	with	Rim+WIN	than	
vehicle	 (P	<	0.01,	 in	 the	 dorsal	 CPu)	 or	 when	 compared	 to	 either	
WIN	or	Rim	alone	(P	<	0.05,	P	<	0.01;	respectively,	in	the	dorsal	CPu)	
(Figure	2,	panel	F).
3.3 | Effects of stress under drug influence
A	2-	way	ANOVA	reported	a	significant	interaction	between	the	factors	
(stress	×	drug)	on	total	distance	traveled	in	the	OF	arena	(F(3,	121)	=	2.76,	
P	<	0.05),	2-	AG	content	(F(3,	23)	=	18.91,	P	<	0.001,	in	the	PFC),	and	fold	
change	expression	for	Chrna6	(F(3,	43)	=	7.38,	P	<	0.001,	in	the	PFC)	and	
Slc6a4	gene	(F(3,	43)	=	3.18,	P	<	0.05,	in	the	PFC).	Simple	main	effects	of	
the	interaction	between	the	factors	are	depicted	in	Table	S2.
In	 an	 OF	 arena,	 repeated	 long-	term	 exposure	 to	 psychosocial	
stress	exacerbated	general	motor	activity	 following	vehicle	admin-
istration	 (Figure	3,	panel	A).	 Indeed,	 social	defeat	animals	exposed	
to	 vehicle	 traveled	 longer	 distances	 than	 their	 controls	 (P	<	0.01)	
(Figure	3,	 panel	 A).	 However,	 the	 pharmacological	 treatment	with	
WIN	reduced	the	total	distance	traveled	in	the	OF	when	compared	
to	 Rim-	treated	 animals	 under	 either	 control	 or	 stress	 conditions	
(P	<	0.01)	(Figure	3,	panel	A).	Likewise,	psychosocially	stressed	mice	
exposed	 to	 the	CB1	 agonist	WIN	 alone	 traveled	 smaller	 distances	
than	the	vehicle	group	(P	<	0.01)	(Figure	3,	panel	A).	The	administra-
tion	of	 the	 inverse	agonist	 in	controls	enhanced	the	 total	distance	
traveled	 when	 compared	 to	 vehicle-	exposed	 animals	 (P	<	0.05)	
F IGURE  2 Effects	of	cannabinoid	drugs	administration.	Data	are	expressed	as	mean	±	SEM.	In	the	OF,	the	cannabinoid	agonist	WIN	
decreased	t	and	the	total	distance	traveled	(P	<	0.01)	(panel	A)	while	the	administration	of	the	inverse	agonist	Rim	significantly	antagonized	such	
effects	(P	<	0.01)	(panel	A).	Coadministration	with	both	cannabinoid	drugs	clearly	reduced	the	total	distance	traveled	in	comparison	to	those	
animals	single	treated	with	Rim	(P	<	0.05)	(panel	A).	The	distance	traveled	in	center	was	statistically	higher	in	animals	treated	with	Rim	alone	
than	those	mice	single	treated	with	the	agonist	(P	<	0.01)	(panel	B).	We	reported	that	animals	treated	simultaneously	with	both	drugs	showed	
more	frequent	rearing	activity	in	their	homecage	than	those	animals	treated	with	WIN	alone	(P	<	0.05)	(panel	C).	We	found	bigger	amount	of	
PEA	and	OEA	in	mice	subjected	to	single	administration	with	the	agonist	in	comparison	with	the	remaining	drug-	treated	groups	(P	<	0.05,	in	the	
dorsal	CPu)	(panel	D	&	E).	We	measured	higher	transcription	rate	for	Fkbp5	gene	following	administration	with	Rim+WIN	than	the	vehicle	group	
(P	<	0.01,	in	the	dorsal	CPu)	or	when	compared	to	either	WIN	or	Rim	alone	(P	<	0.05,	P	<	0.01;	respectively,	in	the	dorsal	CPu)	(panel	F).	An	*	
indicates	significant	differences	between	drug-	treated	mice	and	their	respective	vehicle	group.	Comparisons	between	WIN-	treated	mice	and	
remaining	drug	treatments	are	indicated	by	an	§.	Otherwise	underlined	+	indicated	other	significant	comparison	intragroup.	One	or	two	symbols	
indicate	P < 0.05; P	<	0.01,	respectively.	N	=	15	for	behavioral	testing,	n	=	4	for	endocannabinoids	quantification;	n	=	5	for	whole-	genome	gene	
expression.	PFC,	prefrontal	cortex;	dorsal	CPu,	dorsal	striatum;	OF,	open	field
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(Figure	3,	 panel	A).	Upon	 long-	lasting	 effects	 of	 stress,	 coadminis-
tration	with	Rim+WIN	reduced	the	 total	distance	 traveled	 in	com-
parison	with	 vehicle	 (P	<	0.01)	 and	 Rim-	treated	 animals	 (P	<	0.01)	
(Figure	3,	panel	A).
On	the	other	hand,	controls	only	treated	with	Rim	exhibited	higher	
2-	AG	levels	than	either	vehicle	or	Rim+WIN-	treated	mice	(P	<	0.05,	in	
the	PFC)	(Figure	3,	panel	B).	However,	social	defeat	mice	treated	with	
Rim+WIN	 displayed	 higher	 amounts	 of	 2-	AG	 than	 their	 nonstressed	
counterparts	(P	<	0.01,	in	the	PFC)	but	also	when	compared	to	either	
vehicle,	WIN,	or	Rim	alone	under	stress	(P	<	0.01,	in	the	PFC)	(Figure	3,	
panel	B).	The	administration	of	the	inverse	agonist	Rim	by	the	end	of	
the	stress	period	reduced	the	levels	of	2-	AG	when	compared	to	controls	
treated	with	the	same	drug	(P	<	0.01,	in	the	PFC)	(Figure	3,	panel	B).
Whole-	genome	 gene	 expression	 revealed	 10	 top	 hits	 genes	 de-
regulated	 simultaneously	 by	 stress	 and	 cannabinoid	 administration	
before	Benjamini-	Hochberg	adjustment	(Figure	S1)	(Table	1).	Three	of	
them	(Fkbp5,	Chrna6, and Slc6a4)	were	further	analyzed	by	quantitative	
RT-	PCR.	Two-	way	ANOVA	showed	a	significant	effect	of	the	interac-
tion	on	Slc6a4	 (F(3,	43)	=	3.18,	P	<	0.05)	and	Chrna6	 (F(3,	43)	=	7.38,	
P	<	0.001)	in	the	PFC	but	did	not	reveal	differences	in	the	dorsal	CPu.	
The	use	of	synthetic	cannabinoid	drugs	diminished	the	expression	of	
Chrna6	 in	controls	 (P	<	0.05,	 in	 the	PFC)	 (Figure	3,	panel	C)	and	also	
did	so,	but	not	significantly,	when	WIN	was	administered	 in	stressed	
animals.	 In	 contrast,	 the	 inverse	 agonist	Rim	 clearly	 antagonized	 the	
effects	of	WIN	on	Chrna6	expression	under	stress	(P	<	0.01,	in	the	PFC)	
(Figure	3,	panel	C).	Furthermore,	Rim+WIN	administration	in	stressed	
mice	slightly	decreased	 the	expression	of	Chrna6	when	compared	 to	
Rim	 alone,	 although	Chrna6	 expression	was	 higher	 than	with	 single	
WIN	treatment	(P	<	0.05,	in	the	PFC)	(Figure	3,	panel	C).	By	the	end	of	
the	stress	protocol,	acute	injection	with	Rim	increased	the	expression	
of	Chrna6	in	contrast	to	vehicle	(P	<	0.01,	in	the	PFC)	(Figure	3,	panel	
C).	Social	defeat	animals	exposed	to	either	Rim+WIN	or	Rim	alone	un-
derwent	an	upregulation	of	Chrna6	expression	when	compared	to	their	
nonstressed	counterparts	 (P	<	0.01,	 in	the	PFC)	(Figure	3,	panel	C).	 It	
F IGURE  3 Effects	of	repeated	exposure	to	psychosocial	stress	following	acute	cannabinoid	drugs	administration.	Data	are	expressed	as	
mean	±	SEM.	(1)	Effects on mice behavior:	In	an	open-	field	arena,	exposure	to	psychosocial	stress	exacerbated	general	motor	activity	following	
vehicle	administration	(panel	A-	B).	However,	psychosocially	stressed	mice	exposed	to	the	agonist	WIN	alone	traveled	smaller	distances	than	the	
vehicle	group	(P	<	0.01)	(panel	A).	The	administration	of	inverse	agonist	Rim	in	controls	enhanced	the	total	distance	traveled	when	compared	
to	vehicle	(P	<	0.05)	(panel	A).	(2)	Effects on endocannabinoids levels:	Controls	treated	with	Rim	alone	underwent	an	increase	in	2-	AG	levels	
when	compared	to	either	vehicle	or	Rim+WIN-	treated	mice	(P	<	0.05,	in	the	PFC)	(panel	B).	The	administration	of	the	inverse	agonist	Rim	by	
the	end	of	stress	period	reduced	the	levels	of	the	endocannabinoid	2-	AG	when	compared	to	controls	that	received	the	same	drug	treatment	
(P	<	0.01,	in	the	PFC)	(panel	B).	(3)	Effects on gene expression:	The	use	of	synthetic	cannabinoid	drugs	decreased	the	expression	of	Chrna6 in 
controls	(P	<	0.05,	in	the	PFC)	(panel	C)	and	also	did	but	not	significantly	when	WIN	was	administered	upon	stress	exposure	while	the	inverse	
agonist	Rim	clearly	antagonized	such	effects	(P	<	0.01,	in	the	PFC)	(panel	C).	Social	defeat	animals	cotreated	with	Rim+WIN	or	treated	with	
Rim	alone	underwent	a	remarkable	upregulation	of	Chrna6	expression	when	compared	to	their	nonstressed	counterparts	(P	<	0.01,	in	the	PFC)	
(panel	C).	We	assessed	a	higher	transcription	rate	for	Slc6a4	gene	in	controls	upon	injection	with	the	inverse	agonist	in	comparison	with	the	
remaining	control	groups	(P	<	0.01,	in	the	PFC)	and	also	when	this	drug	was	administered	in	stressed	animals	(P	<	0.01,	in	the	PFC)	(panel	D).	
The	remaining	comparisons	are	depicted	in	the	graph.	An	*	indicates	significant	differences	between	stress	groups	and	their	respective	control	
group.	Control	or	stress	intragroup	comparisons	between	vehicle	and	treated	mice	are	indicated	by	an	§.	Otherwise	underlined	+	indicated	
intragroup	comparisons	between	treatment	groups	in	control	or	stress	conditions.	One	or	two	symbols	indicate	P < 0.05; P	<	0.01,	respectively.	
N	=	15	for	behavioral	testing,	n	=	4	for	endocannabinoids	quantification;	n	=	5	for	whole-	genome	gene	expression.	PFC,	prefrontal	cortex;	CTR,	
control;	STS,	stress
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was	generally	observed	that	in	the	PFC,	the	expression	of	Slc6a4	tran-
scripts	was	higher	in	the	control	group	treated	with	the	inverse	agonist	
Rim	compared	to	all	the	groups	(P	<	0.01,	in	the	PFC,	Figure	3,	panel	D).
4  | DISCUSSION
Long-	term	 stress	 confers	 risk	 to	 develop	 psychiatric	 disorders	 and	
symptoms.25	 In	response	to	prolonged	stress,	glucocorticoid	release	
has	been	shown	to	have	deleterious	effects	on	different	brain	regions	
and	also	is	associated	with	the	regression	of	synapses	and	dendritic	
spines.26	 Remarkably,	 dysfunctions	 in	 corticostriatal	 connectivity	
have	been	involved	in	the	pathophysiology	of	psychiatric	disorders.27 
Moreover,	 the	G	protein-	coupled	CB1	 is	 extremely	 abundant	 and	 a	
key	modulator	of	the	corticostriatal	pathways.10
4.1 | Effects of stress
After	 2	weeks	 of	 daily	 psychosocial	 stress,	 animals	 showed	 loss	 of	
body	weight	in	line	with	Iniguez	et	al.28	Our	data	revealed	that	chronic	
psychosocial	 stress	 exacerbates	 scratching	 activity.29	 The	 endocan-
nabinoid	system	has	been	described	to	have	a	direct	effect	on	sero-
tonergic	neurotransmission	which	in	turn,	modulates	several	behaviors	
and	physiological	functions16	such	as	itch	sensation.30	Moreover,	the	
pronounced	scratching	phenotype	reported	here	could	also	be	attrib-
utable	to	the	lower	levels	of	AEA	observed	in	the	PFC.
In	 fact,	 pharmacological	manipulation	of	 the	degrading	enzymes	
leading	to	increased	levels	of	AEA	has	shown	a	promising	tool	for	re-
ducing	itch	sensation.31	Additionally,	mice	with	defective	endocanna-
binoid	signaling	at	CB1	 receptors	displayed	a	pronounced	scratching	
behavior	(for	review	see	Ref.	[32]).
Stress	is	well	known	to	affect	urinary	bladder	function	and	exac-
erbates	signs	of	urinary	bladder	dysfunction.	We	demonstrated	that	
socially	defeated	animals	urinated	more	frequently	probably	caused	by	
reduced	bladder	capacity	as	described.33
A	decrease	in	motor	activity	is	among	the	changes	most	commonly	
noted	in	subordinates	and	defeated	animals.3	However,	we	found	that	
social	defeat	animals	traveled	longer	distances	in	the	OF	arena.	These	
discrepancies	 could	 be	 attributable	 to	 methodological	 differences	
such	as:	(i)	the	use	of	mice	rather	than	rats;	(ii)	housing	conditions	(five	
mice	to	a	cage	instead	of	just	one);	and	(iii)	the	time	at	testing,	as	here	
the	 stress	 protocol	 and	 drug	 administration	were	 performed	 during	
the	 active	phase	 (after	 8	pm)	 instead	of	 the	 sleep	phase.	 Finally,	we	
measured	an	overexpression	of	Chrna6	under	stress.	Studies	of	genetic	
linkage	reported	that	the	coding	Chrna6	region	confers	risk	to	develop	
neuropsychiatric	 disorders.34	 Likewise,	 Kimbrel	 et	al35	 reported	 that	
two	 SNPs	 linked	 to	 CHRNA6	 conferred	 risk	 for	 developing	 post-	
traumatic	stress	disorder.	Thus,	the	results	described	here	point	out	a	
plausible	contribution	of	Chrna6	to	the	long-	lasting	effects	observed	
in	social	defeat	animals.
4.2 | Effects of drug administration
Single	 administration	 of	 the	 agonist	 WIN	 reduced	 total	 distance	
traveled	while	acute	treatment	with	the	inverse	agonist	Rim	slightly	
increased	it	when	compared	to	controls	an	observation	corroborated	
by	Brzozka	et	al.3
In	the	OF,	mice	treated	with	the	inverse	agonist	Rim	traveled	lon-
ger	distances	in	the	center	than	the	remaining	groups,	which	support	
an	anxiolytic	effect	mediated	by	the	drug,36	even	though	CB1	antag-
onism	 can	 also	 produce	 anxiogenic	 actions.37	 Animals	 treated	with	
Rim+WIN	showed	more	frequent	rearing	behavior	than	WIN-	treated	
animals.	 Indeed,	 cannabis	 smoke	 exposure	 induced	 lower	 rearing	
activity,	while	 the	use	of	Rimonabant	prevented	 the	smoke-	induced	 
decrease	in	rearing.38
Upon	CB1	activation	by	WIN,	we	observed	an	increase	in	the	levels	
of	both	OEA	and	PEA,	two	mediators	metabolically	related	to	AEA.	In	
line	with	our	results,	Bardou	et	al39	reported	an	increase	in	OEA	and	
PEA	contents	after	inhibiting	the	enzyme	fatty	acid	amide	hydrolase.	
Despite	the	fact	that	OEA	and	PEA	levels	often,	but	not	always,	change	
TABLE  1 Differentially	deregulated	top	10	genes	in	response	to	chronic	psychosocial	stress	and	acute	cannabinoid	treatment
Genes PFC DS FC Stress FC Rim FC WIN q value Stress q value Rim q value WIN
Chrna6 33.8 45.6 13.5 −13.2 −15.2 6.46E-	11 0 0
Slc6a4 64.2 102.3 31.7 −34.1 −32.5 1 1 0
Ldlr 7.5 7.7 −0.2 −0.3 −0.1 0.7 0.01 1
Sdf2l1 5.6 5.3 0.5 0.5 0.2 0.002 0.02 1
Lrg1 4.1 2.5 0.5 0.7 0.5 0.1 0.02 1
Fkbp5 7.8 8.0 0.5 0.4 0.2 4.81E-	06 0.03 1
Dok3 5.2 4.9 0.4 0.5 0.1 0.1 0.03 1
Hspa5 10.7 10.8 0.3 0.3 0.2 0.01 0.05 1
Manf 7.9 7.9 0.2 0.2 0.1 0.01 0.05 1
Hspa1a 6.8 6.0 0.3 0.4 0.2 0.03 0.05 1
Column	titles	from	left	to	right:	official	gene	symbol;	PFC,	prefrontal	cortex;	dorsal	CPu,	dorsal	striatum;	FC	stress,	fold	change	stress;	FC	Rim,	fold	change	
Rimonabant;	FC	WIN,	fold	change	WIN55212.2;	q	value	Stress,	P	adjust	value	Stress;	q	value	Rim,	P	adjust	value	Rimonabant;	q	value	WIN,	P	adjust	value	
WIN55212.2.
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in	a	similar	manner	to	those	of	AEA	under	physiological	or	pathological	
conditions,	we	did	not	observe	here	any	similar	changes	in	AEA	levels	
following	chronic	psychosocial	stress.	This	finding	is	compatible	with	
the	general	concept	 that	OEA	and	PEA	are	not	eCBs	 in	as	much	as	
they	do	not	activate	directly	CB1	and	CB2	receptors,	but	instead	mod-
ulate	noncannabinoid	receptors,	such	as	G	protein-	coupled	receptor	
55	 (GPR55),	 peroxisome	 proliferator-	activated	 receptor-	α	 (PPAR-	α),	
and	 transient	 receptor	 potential	 vanilloid	 type-	1	 (TRPV1)	 channels.	
Recently,	Musella	et	al	reported	that	significant	levels	of	PEA	are	pres-
ent	in	the	striatum,	where	this	mediator	enhances	GABAergic	neuro-
transmission	via	GPR55.	Interestingly,	PEA	was	previously	reported	to	
exhibit	greater	binding	affinity	for	GPR55	than	CB1,	CB2,	PPAR-	α,	and	
TRPV1	(for	review	see	Ref.	[40]).	Thus,	it	 is	noteworthy	to	speculate	
that	exposure	to	cannabinoid	drugs,	by	altering	PEA	levels,	modifies	
GPR55	receptor	activity.
It	 is	well	 known	 that	 the	glucocorticoid	 receptor	 is	 regulated	by	
several	chaperones	and	cochaperones	including	the	FKBP5	protein.41 
In	particular,	we	found	that	the	administration	of	the	CB1	inverse	ag-
onist	 Rimonabant	 potentiated	 the	 expression	 of	 Fkbp5	 when	 com-
pared	to	the	remaining	groups.	This	is	in	agreement	with	data	showing	
that	 FKBP5	 regulates	 glucocorticoid	 receptor	 sensitivity,	 increases	
its	resistance,	and	decreases	its	efficiency	at	controlling	the	negative	
feedback	in	response	to	elevated	levels	of	corticosterone,42	whereas	
Rimonabant	 can	aggravate	 the	hyperactivity	of	 the	HPA	axis	during	
stress.43	Several	studies	attest	to	the	idea	that	FKBP5	is	crucial	for	the	
development	of	stress-	related	mental	disorders	 (44,45).	However,	 it	 is	
currently	unclear	how	the	activation	of	the	endocannabinoid	system	
through	 the	use	of	 synthetic	cannabinoid	drugs	may	 regulate	either	
Fkbp5	or	glucocorticoid	 signaling	as	pointed	out	by	Wang	et	al.46 In 
conclusion,	our	understanding	of	FKBP5	functions	is	still	 incomplete	
and	thus,	further	work	must	address	this	question.
4.3 | Effects of stress under drug influence
The	inverse	agonist	Rimonabant	in	nonstress	conditions	antagonized	
the	effects	of	WIN55212.2	on	total	distance	travelled.3	Under	experi-
mentally	induced	psychosocial	stress,	mice	treated	with	either	WIN	or	
Rim+WIN	showed	less	total	distance	traveled	than	the	vehicle	group,	
while	 single	 Rimonabant	 administration	 antagonized	 the	 effects	 of	
WIN.3	We	also	observed	that	stressed	mice	exposed	to	vehicle	dis-
played	an	exacerbated	total	distance	traveled	when	compared	to	their	
nonstressed	counterparts.	Against	the	present	findings,	Brzozka	et	al3 
found	that	repeated	exposure	to	social	defeat	paradigm	reduced	the	
total	distance	traveled	in	the	OF.	The	differences	reported	here	could	
be	explained	by	the	influence	of	the	circadian	rhythm	and	the	hous-
ing	conditions	(5	mice	per	cage	instead	of	just	one).	Indeed,	mice	are	
nocturnal	animals	mainly	active	during	the	dark	period.5	Furthermore,	
the	absence	of	social	support	(individual	housing)	amplifies	the	anxiety	
induced	by	psychosocial	stress.47
It	 is	 widely	 accepted	 that	 upon	 HPA	 activation,	 the	 content	 of	
endocannabinoid	 lipid	 molecules	 varies	 according	 to	 the	 duration/
type	of	 stress	 stimuli	 and	 the	brain	 structure.	We	 found	 that	 social	
defeat	 animals	 exposed	 to	vehicle	 showed	 similar	 2-	AG	 levels	 than	
their	controls	in	agreement	with.48	In	contrast,	Gorzalka	et	al49	deter-
mined	 that	 after	 chronic	 stress,	 the	 endocannabinoid	 signaling	was	
compromised	 because	 endocannabinoid	 levels	 were	 reduced	 in	 all	
limbic	structures.	Chronic	restraint	stress,	for	example,	progressively	
increases	2-	AG	content	within	distinct	anatomical	regions	such	as	the	
medial	PFC,	 limbic	forebrain,	amygdala,	hippocampus,	and	hypothal-
amus.50	These	differences	could	be	explained	by	the	influence	of	the	
circadian	rhythm	and	also	related	to	the	stress	protocol	used.	In	fact,	
there	is	a	strong	evidence	to	suggest	that	 in	rodents	circadian	alter-
ations	occur	in	endocannabinoid	brain	levels,51	CB1	expression,
52 and 
the	activity	of	enzymes	controlling	 the	metabolism	of	endocannabi-
noids.51	The	administration	of	Rimonabant	 in	controls	as	well	as	the	
pharmacological	 blockade	of	MAGL	enzyme	has	been	 reported	 in	 a	
powerful	 increase	of	2-	AG	 levels	 in	 the	CNS.53	Here,	 such	 increase	
was	also	observed	when	both	cannabinoids	were	administered	but	not	
when	Rim	was	injected	alone.	Thus,	the	use	of	synthetic	cannabinoids	
in	this	model	warrants	further	investigation	in	order	to	elucidate	the	
underlying	mechanisms	associated	with	the	metabolism	of	2-	AG.
Not	surprisingly,	we	found	that	the	cannabinoid	agonist	WIN	and	
the	 inverse	 agonist	 Rim	 influenced	 the	 expressions	 of	 Chrna6 and 
Slc6a4	 in	 opposite	 directions,	 while	 their	 coadministration	 tended	
to	 produce	 a	 net	 null	 effect	 under	 experimentally	 induced	 psycho-
social	 stress.	 Nicotinic	 receptor	 containing	 α6	 subunit	 (CHRNA6)	 is	
expressed	in	distinct	brain	regions	important	for	addiction	behaviors	
and	also	is	identified	to	confer	susceptibility	to	neuropsychiatric	disor-
ders.34	In	line	with	this	report,	emerging	data	point	out	that	the	coding	
region	for	CHRNA6	confers	vulnerability	to	drugs	of	abuse	and	their	
related	behavioral	phenotypes.54	Interestingly,	the	present	investiga-
tion	is	the	first	to	demonstrate	that	simultaneous	exposure	to	distinct	
environmental	 factors	 such	as	chronic	 stress	and	acute	cannabinoid	
drug	administration	can	 regulate	 the	expression	of	 the	Chrna6	gene	
which	in	turn	and	could	be	crucial	for	the	development	of	cannabis	ad-
diction	and	psychosis.	Long-	term	exposure	to	stress	constitutes	a	key	
environmental	risk	component	for	developing	stress-	related	disorders	
in	 susceptible	 individuals.	 The	 underlying	 mechanisms	 disrupted	 in	
these	disorders	are	serotonergic55 and endocannabinoid56	dependent.	
Particularly,	serotonin	release	inhibition	is	attributable	to	the	 lack	of	
CB1	 receptors	which	 in	 turn,	 promotes	 higher	 concentration	 of	 this	
neurotransmitter	in	the	synaptic	cleft.57	Then,	we	can	speculate	that	
CB1	blockage	by	the	administration	of	Rim	could	counteract	the	ex-
cessive	serotonin	neurotransmitter	by	increasing	the	expression	of	the	
serotonin	transporter	protein	(Slc6a4).58	Furthermore,	SLC6A4	single	
nucleotide	 polymorphisms	 have	 been	 associated	with	 stress-	related	
psychiatric	disorders,59	which	are	consistent	with	our	findings.
5  | CONCLUSIONS
In	summary,	the	data	described	here	highlight	the	effects	of	long-	term	
exposure	to	stress	on	mouse	corticostriatal	circuitries	following	acute	
challenge	with	distinct	cannabinoid	drugs	(For	further	details	see	Figure	
S2).	Particularly,	we	found	that	psychological	stress	played	a	role	in	the	
exacerbation	of	micturition	frequency,	anxiety-	related	behavior,58 and 
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scratching	phenotype,29	while	the	use	of	synthetic	cannabinoids	drugs	
interfered	with	locomotor	activity,	rearing,	and	anxiety-	like	behavior.38 
The	 glucocorticoid	 receptor	 is	 regulated	 by	 several	 chaperones	 and	
cochaperones	including	the	FKBP5	protein41	but	also	is	influenced	by	
endocannabinoid	 system.17	Additionally,	we	demonstrated	 that	psy-
chosocially	 stressed	 animals	 displayed	 changes	 in	 the	 serotonergic	
system	 upon	 acute	 exposure	 to	 synthetic	 cannabinoid	 drugs.55	 The	
coding	region	for	CHRNA6	confers	vulnerability	to	drugs	of	abuse	and	
their	related	behavioral	phenotypes,54	which	in	turn,	could	be	crucial	
for	the	development	of	cannabis	addiction	and	psychosis.	Our	findings	
in	both	PFC	and	dorsal	CPu	need	to	be	corroborated	by	further	studies	
if	we	want	to	understand	the	role	of	CB1 and endocannabinoids and 
related	mediators	in	corticostriatal	signaling	under	psychosocial	stress.
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